CABs

LAT CAB (2021-present)

Funded by the Unitaid LONGEVITY project, the LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, HIV, and latent TB infection.

Materials in this section

About

LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, HIV, and LTBI. More

CABsLAT CAB (2021-present)